Cargando…

Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database

OBJECTIVE: Metformin-associated lactic acidosis (MaLA) occurs rarely and is thus difficult to study. We analysed 4241 individual case safety reports of lactic acidosis (LA) that implicated metformin as a suspected drug reported to the pharmacovigilance database of Merck KGaA, Darmstadt, Germany. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Brand, Kerstin M G, Schlachter, Judith, Foch, Caroline, Boutmy, Emmanuelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642855/
https://www.ncbi.nlm.nih.gov/pubmed/36389204
http://dx.doi.org/10.2147/TCRM.S372430
_version_ 1784826399962431488
author Brand, Kerstin M G
Schlachter, Judith
Foch, Caroline
Boutmy, Emmanuelle
author_facet Brand, Kerstin M G
Schlachter, Judith
Foch, Caroline
Boutmy, Emmanuelle
author_sort Brand, Kerstin M G
collection PubMed
description OBJECTIVE: Metformin-associated lactic acidosis (MaLA) occurs rarely and is thus difficult to study. We analysed 4241 individual case safety reports of lactic acidosis (LA) that implicated metformin as a suspected drug reported to the pharmacovigilance database of Merck KGaA, Darmstadt, Germany. The primary objective was to review reports for quality and completeness of data to support diagnoses of MaLA. We also explored the correlations between reported biomarkers, and associations between biomarkers and outcomes. RESEARCH DESIGN AND METHODS: Records were analysed for completeness in supporting diagnoses of LA or metformin-associated LA (MaLA), against commonly used diagnostic criteria. Correlations between indices of exposure to metformin and biomarkers of LA and mortality were investigated. RESULTS: Missing data was common, especially for plasma metformin. Clinical/biomarker evidence supported a diagnosis of LA in only 33% of cases (LA subpopulation) and of MaLA in only 9% (MaLA subpopulation). The metformin plasma level correlated weakly with plasma lactate (positive) and pH (negative). About one-fifth (21.9%) of cases reported a fatal outcome. Metformin exposure (plasma level or dose) was not associated with increased mortality risk (there was a suggestion of decreased risk at higher levels of exposure to metformin). Plasma lactate was the only variable associated with increased risk of mortality. Examination of concomitant risk factors for MaLA identified renal dysfunction (including of iatrogenic origin) as a potential driver of mortality in this population. CONCLUSION: Despite the high frequency of missing data, this is the largest analysis of cases of MaLA supported by measurements of circulating metformin, and lactate, and pH, to date. Plasma lactate, and not metformin dose or plasma level, appeared to be the main driver of mortality in the setting of LA or MaLA. Further research with more complete case reports is required.
format Online
Article
Text
id pubmed-9642855
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96428552022-11-15 Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database Brand, Kerstin M G Schlachter, Judith Foch, Caroline Boutmy, Emmanuelle Ther Clin Risk Manag Original Research OBJECTIVE: Metformin-associated lactic acidosis (MaLA) occurs rarely and is thus difficult to study. We analysed 4241 individual case safety reports of lactic acidosis (LA) that implicated metformin as a suspected drug reported to the pharmacovigilance database of Merck KGaA, Darmstadt, Germany. The primary objective was to review reports for quality and completeness of data to support diagnoses of MaLA. We also explored the correlations between reported biomarkers, and associations between biomarkers and outcomes. RESEARCH DESIGN AND METHODS: Records were analysed for completeness in supporting diagnoses of LA or metformin-associated LA (MaLA), against commonly used diagnostic criteria. Correlations between indices of exposure to metformin and biomarkers of LA and mortality were investigated. RESULTS: Missing data was common, especially for plasma metformin. Clinical/biomarker evidence supported a diagnosis of LA in only 33% of cases (LA subpopulation) and of MaLA in only 9% (MaLA subpopulation). The metformin plasma level correlated weakly with plasma lactate (positive) and pH (negative). About one-fifth (21.9%) of cases reported a fatal outcome. Metformin exposure (plasma level or dose) was not associated with increased mortality risk (there was a suggestion of decreased risk at higher levels of exposure to metformin). Plasma lactate was the only variable associated with increased risk of mortality. Examination of concomitant risk factors for MaLA identified renal dysfunction (including of iatrogenic origin) as a potential driver of mortality in this population. CONCLUSION: Despite the high frequency of missing data, this is the largest analysis of cases of MaLA supported by measurements of circulating metformin, and lactate, and pH, to date. Plasma lactate, and not metformin dose or plasma level, appeared to be the main driver of mortality in the setting of LA or MaLA. Further research with more complete case reports is required. Dove 2022-11-04 /pmc/articles/PMC9642855/ /pubmed/36389204 http://dx.doi.org/10.2147/TCRM.S372430 Text en © 2022 Brand et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Brand, Kerstin M G
Schlachter, Judith
Foch, Caroline
Boutmy, Emmanuelle
Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database
title Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database
title_full Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database
title_fullStr Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database
title_full_unstemmed Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database
title_short Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database
title_sort quality and characteristics of 4241 case reports of lactic acidosis in metformin users reported to a large pharmacovigilance database
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642855/
https://www.ncbi.nlm.nih.gov/pubmed/36389204
http://dx.doi.org/10.2147/TCRM.S372430
work_keys_str_mv AT brandkerstinmg qualityandcharacteristicsof4241casereportsoflacticacidosisinmetforminusersreportedtoalargepharmacovigilancedatabase
AT schlachterjudith qualityandcharacteristicsof4241casereportsoflacticacidosisinmetforminusersreportedtoalargepharmacovigilancedatabase
AT fochcaroline qualityandcharacteristicsof4241casereportsoflacticacidosisinmetforminusersreportedtoalargepharmacovigilancedatabase
AT boutmyemmanuelle qualityandcharacteristicsof4241casereportsoflacticacidosisinmetforminusersreportedtoalargepharmacovigilancedatabase